{"id":451134,"date":"2021-03-04T14:08:09","date_gmt":"2021-03-04T19:08:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451134"},"modified":"2021-03-04T14:08:09","modified_gmt":"2021-03-04T19:08:09","slug":"shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/","title":{"rendered":"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n MILWAUKEE<\/span>, March 4, 2021<\/span> \/PRNewswire\/ —\u00a0Ademi LLP is investigating Five Prime\u00a0(NASDAQ: FPRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen. <\/p>\n

Click here to learn how to join the action: http:\/\/ademilaw.com\/case\/five-prime-therapeutics<\/a> or call Guri Ademi<\/span> toll-free at 866-264-3995.\u00a0 There is no cost or obligation to you. <\/p>\n

Ademi LLP alleges\u00a0Five Prime’s financial outlook is excellent and yet Five Prime shareholders will receive only $38<\/span> per each share of Five Prime stock. \u00a0The merger agreement unreasonably limits competing bids for Five Prime\u00a0by prohibiting solicitation of further bids, and imposing a termination penalty if Five Prime\u00a0accepts a superior bid. Five Prime\u00a0insiders will receive millions of dollars as part of change of control arrangements. We are investigating the conduct of Five Prime’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Five Prime. <\/p>\n

If you own Five Prime\u00a0common stock and wish to obtain additional information, please contact Guri Ademi<\/span> either at gademi@ademilaw.com<\/a>\u00a0or toll-free: 866-264-3995, or http:\/\/ademilaw.com\/case\/five-prime-therapeutics<\/a>. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. <\/p>\n

\n Contacts<\/b>\n <\/p>\n

Ademi LLP
Guri Ademi<\/span>
Toll Free: (866) 264-3995
Fax: (414) 482-8001<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen-301240946.html<\/a><\/p>\n

SOURCE Ademi LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire MILWAUKEE, March 4, 2021 \/PRNewswire\/ —\u00a0Ademi LLP is investigating Five Prime\u00a0(NASDAQ: FPRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen. Click here to learn how to join the action: http:\/\/ademilaw.com\/case\/five-prime-therapeutics or call Guri Ademi toll-free at 866-264-3995.\u00a0 There is no cost or obligation to you. Ademi LLP alleges\u00a0Five Prime’s financial outlook is excellent and yet Five Prime shareholders will receive only $38 per each share of Five Prime stock. \u00a0The merger agreement unreasonably limits competing bids for Five Prime\u00a0by prohibiting solicitation of further bids, and imposing a termination penalty if Five Prime\u00a0accepts a superior bid. Five Prime\u00a0insiders will receive millions of dollars as part of change of control arrangements. We … <\/p>\n

Continue reading “Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451134","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nShareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MILWAUKEE, March 4, 2021 \/PRNewswire\/ —\u00a0Ademi LLP is investigating Five Prime\u00a0(NASDAQ: FPRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen. Click here to learn how to join the action: http:\/\/ademilaw.com\/case\/five-prime-therapeutics or call Guri Ademi toll-free at 866-264-3995.\u00a0 There is no cost or obligation to you. Ademi LLP alleges\u00a0Five Prime’s financial outlook is excellent and yet Five Prime shareholders will receive only $38 per each share of Five Prime stock. \u00a0The merger agreement unreasonably limits competing bids for Five Prime\u00a0by prohibiting solicitation of further bids, and imposing a termination penalty if Five Prime\u00a0accepts a superior bid. Five Prime\u00a0insiders will receive millions of dollars as part of change of control arrangements. We … Continue reading "Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T19:08:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG99300&sd=2021-03-04\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen\",\"datePublished\":\"2021-03-04T19:08:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/\"},\"wordCount\":268,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG99300&sd=2021-03-04\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/\",\"name\":\"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG99300&sd=2021-03-04\",\"datePublished\":\"2021-03-04T19:08:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG99300&sd=2021-03-04\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG99300&sd=2021-03-04\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/","og_locale":"en_US","og_type":"article","og_title":"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen - Market Newsdesk","og_description":"PR Newswire MILWAUKEE, March 4, 2021 \/PRNewswire\/ —\u00a0Ademi LLP is investigating Five Prime\u00a0(NASDAQ: FPRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen. Click here to learn how to join the action: http:\/\/ademilaw.com\/case\/five-prime-therapeutics or call Guri Ademi toll-free at 866-264-3995.\u00a0 There is no cost or obligation to you. Ademi LLP alleges\u00a0Five Prime’s financial outlook is excellent and yet Five Prime shareholders will receive only $38 per each share of Five Prime stock. \u00a0The merger agreement unreasonably limits competing bids for Five Prime\u00a0by prohibiting solicitation of further bids, and imposing a termination penalty if Five Prime\u00a0accepts a superior bid. Five Prime\u00a0insiders will receive millions of dollars as part of change of control arrangements. We … Continue reading \"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T19:08:09+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG99300&sd=2021-03-04","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen","datePublished":"2021-03-04T19:08:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/"},"wordCount":268,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG99300&sd=2021-03-04","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/","name":"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG99300&sd=2021-03-04","datePublished":"2021-03-04T19:08:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG99300&sd=2021-03-04","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG99300&sd=2021-03-04"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-ademi-llp-investigates-whether-five-prime-therapeutics-has-obtained-a-fair-price-in-its-transaction-with-amgen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451134"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451134\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}